EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis

Jiaxin Chen iD, Linge Jian, Yangkun Guo, Chengwei Tang, Zhiyin Huang, Jinhang Gao iD

Antioxidants · 15.06.2024 · 13 (6) · 729

DOI: 10.3390/antiox13060729 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 15.06.2024. Verfasst von Jiaxin Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Fund of China, the 135 projects for disciplines of excellence of West China Hospital, Sichuan University, 135 projects for disciplines of excellence of West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-third of the global population. MASLD and its advanced-stage liver fibrosis and cirrhosis are the leading causes of liver failure and liver-related death worldwide. Mitochondria are crucial organelles in liver cells for energy generation and the oxidative metabolism of fatty acids and carbohydrates. Recently, mitochondrial dysfunction in liver cells has been shown to play a vital role in the pathogenesis of MASLD and liver fibrosis. Mitophagy, a selective form of autophagy, removes and recycles impaired mitochondria. Although significant advances have been made in understanding mitophagy in liver diseases, adequate summaries concerning the contribution of liver cell mitophagy to MASLD and liver fibrosis are lacking. This review will clarify the mechanism of liver cell mitophagy in the development of MASLD and liver fibrosis, including in hepatocytes, macrophages, hepatic stellate cells, and liver sinusoidal endothelial cells. In addition, therapeutic strategies or compounds related to hepatic mitophagy are also summarized. In conclusion, mitophagy-related therapeutic strategies or compounds might be translational for the clinical treatment of MASLD and liver fibrosis.

Schlagwörter

Stichwörter der Autor:innen

Kupffer cells (KCs)hepatic stellate cells (HSCs)hepatocytesliver fibrosisliver sinusoidal endothelial cells (LSECs)macrophagesmetabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)mitochondriamitophagy

Autor:innen und Institutionen

  • Laboratory of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China.

ORCID-Profile: Jiaxin Chen, Jinhang Gao

Förderung

  • National Natural Science Fund of China
  • the 135 projects for disciplines of excellence of West China Hospital, Sichuan University
  • 135 projects for disciplines of excellence of West China Hospital, Sichuan University

Zitieren

APA

Chen, J., Jian, L., Guo, Y., Tang, C., Huang, Z., & Gao, J. (2024). Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis. Antioxidants, 13(6), 729. https://doi.org/10.3390/antiox13060729

Vancouver

Chen J, Jian L, Guo Y, Tang C, Huang Z, Gao J. Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis. Antioxidants. 2024;13(6):729. doi:10.3390/antiox13060729

BibTeX
@article{Chen2024,
  author = {Chen, Jiaxin and Jian, Linge and Guo, Yangkun and Tang, Chengwei and Huang, Zhiyin and Gao, Jinhang},
  title = {Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis},
  journal = {Antioxidants},
  year = {2024},
  volume = {13},
  number = {6},
  pages = {729},
  doi = {10.3390/antiox13060729}
}
Kostenlos starten →